Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.

Abstract

2B1 is a bispecific murine monoclonal antibody (BsMAb) with specificity for the c-erbB-2 and Fc gamma RIII extracellular domains. This BsMAb promotes the targeted lysis of malignant cells overexpressing the c-erbB-2 gene product of the HER2/neu proto-oncogene by human natural killer cells and mononuclear phagocytes expressing the Fc gamma RIII A isoform. In… (More)

Topics

Cite this paper

@article{Weiner1995PhaseIT, title={Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.}, author={Louis M. Weiner and Joseph Clark and Michael P. Davey and Wenwu Li and I E Garcia de Palazzo and David B. Ring and R Katherine Alpaugh}, journal={Cancer research}, year={1995}, volume={55 20}, pages={4586-93} }